A Rapidly Changing AML Landscape: Keeping up With the Newest Advances in AML Management

bookLearning Objectives

  • Discuss current AML treatment strategies and management, including the role of induction and maintenance therapy
  • Describe the therapy options available for maintenance of remission in patients with AML
  • Review the latest clinical evidence for the medications used to treat AML, including for induction and maintenance therapy
  • Integrate the latest evidence into clinical practice to improve patient outcomes



Friday, October 22, 2021

Local Time

  • Timezone: America/New_York
  • Date: Friday, October 22, 2021
  • Time: 12:00 pm - 1:00 pm


Registration is complimentary for healthcare professionals. Please click the button below to complete the transaction:

personAbout the Faculty

Dr. John Storring

Dr. John Storring, MD, CM, FRCPC


Dr. John Storring completed medical school and residency at McGill University in Montreal.  He went on to a fellowship in leukemia and cellular therapy at the Princess Margaret Cancer Centre in Toronto before joining the staff in the Division of Hematology at the McGill University Health Centre.  His main area of clinical focus is acute myeloid leukemia, myelodysplastic syndrome, and stem cell transplantation.  He is the local lead investigator on several national and international clinical trials for these disorders.  He is a member of several major Canadian efforts in this area including the Canadian Myelodysplastic Syndromes Registry and he is on the board of directors of the Canadian Leukemia Study Group (CLSG).



Dr. Gail Roboz, MD


Gail J.Roboz, MD is Professor of medicine and director of the clinical and translational leukemia programs at Weill Cornell Medicine and the New York Presbyterian Hospital in New York. New York, USA.

Dr. Roboz graduated summa cum laude from Yale University and Alpha Omega Alpha from the Mount Sinai School of Medicine, where she also achieved the highest academic standing in the graduating class. Dr. Roboz completed internship in Internal Medicine at the Beth Israel Hospital in Boston and residency at The New York Presbyterian Hospital. She completed fellowship in hematology and medical oncology at Weill Cornell Medical College and The New York Presbyterian Hospital.

Dr. Roboz’s research interests are in developmental therapeutics and novel clinical trial design for acute leukemias, myelodysplastic syndrome, and myeloproliferative disorders. She is the principal investigator on numerous investigator-initiated, cooperative group, and industry-sponsored clinical trials in these areas and has authored many related manuscripts and abstracts. Dr. Roboz serves on the Leukemia Core Committee for the Alliance clinical trials in oncology and is the Weill Cornell Principal Investigator for the MDS Clinical Research Consortium. She chairs the clinical committee of the European Leukemia Net (ELN) working group on minimal residual disease in acute myeloid leukemia. She also serves on the Scientific Advisory Board of the Aplastic Anemia and MDS International Foundation. Dr. Roboz has played an active role as a chair, speaker and panelist at numerous national and international conferences and is the recipient of prestigious honors and awards in the field.

MD Anderson Employee Portrait

Dr. Courtney DiNardo, MD


Dr. DiNardo is an academic clinical researcher with a primary focus on individualized therapy and precision oncology for myeloid malignancies, including the optimal incorporation of genomics into standard risk assessments and treatment algorithms, and the clinical evaluation of targeted therapeutics for molecularly-defined patient subgroups. Dr. DiNardo has experience in designing, overseeing, and executing successful clinical trials; from Phase 1 dose-finding studies to innovative investigator-initiated Phase II trials, to confirmatory randomized Phase III trials. Dr. DiNardo has served an integral role in several highly influential trials involving IDH1, IDH2 and BCL2 inhibitors, which have led to the FDA approval of three therapies in AML since 2017 (the first-in-class IDH2 inhibitor enasidenib, the IDH1 inhibitor ivosidenib, and the BCL2 inhibitor venetoclax in combination with hypomethylating agents).


This program has been made possible through unrestricted support from Bristol Myers Squibb